Physician profile
Brian Kim
NPI 1114022522
$2,159.83
in general payments reported to CMS, 2019-2025
19 companies · $995 in 2025
The $995 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $16.87 · 2022: $53.62 · 2023: $284 · 2024: $810 · 2025: $995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,066 · Education: $23.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,066.16 |
| Education | $23.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,000.91 | 2023-2025 | Biktarvy |
| Viiv Healthcare Company | $333.72 | 2023-2025 | Dovato, Cabenuva |
| Glaxosmithkline, LLC. | $136.04 | 2020-2025 | Ojjaara |
| Caris Mpi, INC. | $128.25 | 2025 | Mi Cancer Seek |
| Madrigal Pharmaceuticals | $118.01 | 2025 | Rezdiffra |
| Lilly USA, LLC | $72.91 | 2024-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $48.66 | 2024-2025 | Veozah |
| Amgen INC. | $42.23 | 2024 | Repatha, Otezla |
| Novo Nordisk INC | $40.15 | 2024-2025 | Ozempic, Rybelsus |
| Emd Serono, INC. | $32.46 | 2024-2025 | |
| Genentech USA, INC. | $30.91 | 2025 | Actemra |
| Acutus Medical, INC. | $29.13 | 2022 | |
| Aurinia Pharma U.S., INC. | $25.09 | 2024 | Lupkynis |
| Teleflex LLC | $24.57 | 2025 | Urolift |
| Janssen Biotech, INC. | $24.49 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $24.00 | 2025 | |
| Phadia US INC. | $18.05 | 2023 | Immunocap |
| Sanofi-Aventis U.S. LLC | $15.66 | 2024 | |
| Exact Sciences Corporation | $14.59 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.